General Information of Drug (ID: DMYR1K8)

Drug Name
S-17092-1 Drug Info
Synonyms
NXSXRIHXEQSYEZ-KNJMJIDISA-N; S 17092; CHEMBL1086968; 176797-26-5; S-17092; s17092; SCHEMBL194654; GTPL6565; DTXSID70433003; ZINC3825778; BDBM50316818; NCGC00485216-01; S 17092, > ((2S,3aS,7aS)-1-((1R,2R)-2-phenylcyclopropanecarbonyl)octahydro-1H-indol-2-yl)(thiazolidin-3-yl)methanone; (2S,3aS,7aS)-1-(((R,R)-2-Phenylcyclopropyl)carbonyl)-2-((thiazolidin-3-yl)carbonyl)octahydro-1H-indole; [(2S,3aS,7aS)-Octahydro-1-[[(1R,2R)-2-phenylcyclopropyl]carbonyl]-1H-indol-2-yl]-3-thiazolidinyl--methanone; S-17092 (undefined isomer); (2S,3aS,7aS)-1-[(1R,2R)-2-Phenylcyclopropylcarbonyl]-2-(thiazolidin-3-ylcarbonyl)perhydroindole
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Phase 1 [1]
Non-small-cell lung cancer 2C25.Y Clinical trial [2]
Cross-matching ID
PubChem CID
9929984
CAS Number
CAS 176797-26-5
TTD Drug ID
DMYR1K8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Prolyl endopeptidase (PREP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [4]
ALV-003 DMXSFA0 Coeliac disease DA95 Phase 2 [5]
ONO-1603 DMKIZAL Cognitive impairment 6D71 Phase 2 [6]
JTP-4819 DMI0UJS Cognitive impairment 6D71 Discontinued in Phase 2 [7]
Z-321 DMLO2QY Parkinson disease 8A00.0 Discontinued in Phase 1 [8]
BAICALIN DMY1TLZ Human immunodeficiency virus infection 1C62 Terminated [9]
Y-29794 DMLAVES N. A. N. A. Terminated [9]
Double Oxidized Cysteine DM6TU84 Discovery agent N.A. Investigative [10]
Monothioglycerol DMENSOZ Discovery agent N.A. Investigative [10]
Z-Pro-Prolinal DM43O2U Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prolyl endopeptidase (PREP) TTNGKET PPCE_HUMAN Inhibitor [3]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011104)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6565).
3 Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29.
4 Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
5 The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
6 ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
7 A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51.
8 Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6.
9 Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
10 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.